Hospital Lusiadas Porto
- Address
- lock Available on a paid plan
Neoplasms and Medical Oncology
At Hospital Lusiadas Porto, clinical research in neoplasms focuses on advanced breast cancer and the search for better ways to control disease progression. The trials are designed to evaluate the effectiveness and safety of new treatment approaches for people with hormone receptor-positive, HER2-negative breast cancer.
- Assessing new cancer therapy combinations for advanced breast cancer
- Studying treatment effectiveness in breast cancer care
- Evaluating safety alongside potential benefit for patients with neoplastic disease
These studies reflect a strong interest in improving outcomes in oncology through more targeted and effective treatment options.
Female Urogenital Diseases
Research in female urogenital diseases at this Porto site includes work on overactive bladder, with attention to both symptom relief and patient experience. The trial activity aims to explore whether a new treatment system can offer a practical and acceptable option for people living with bladder control problems.
- Investigating a new approach for overactive bladder
- Looking at symptom management and patient satisfaction
- Gathering feedback on ease of use and treatment acceptability
This area combines urology and patient-centered care, with an emphasis on improving everyday quality of life for individuals affected by bladder symptoms.
Male Urogenital Diseases and Related Urologic Care
Although the current trial portfolio is small, the site’s coverage of male urogenital diseases and broader urologic research indicates interest in conditions affecting the urinary system. The ongoing studies contribute to understanding how new therapies and delivery systems may improve treatment experience and clinical benefit across urinary disorders.
- Exploring treatment options relevant to urinary tract disorders
- Supporting research into bladder health and related symptoms
- Advancing practical care approaches in urology
With Medical Oncology as the main department, the site shows a focused but diverse interest in both cancer care and urinary health research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Lusiadas Porto
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An exploratory, prospective, multicenter, randomized, double blind, placebo + sham device controlled, study to assess the safety, usability, and initial efficacy of the ViXe combination for intravesical administration of XEOMIN® in the treatment of female patients with idiopathic overactive bladder (OAB). | Vensica Medical Ltd. | Phase II | Not Recruiting | Jun 2023 | Feb 2024 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abemaciclib | 1 | Unknown | 2025-04-07 | 2025-04-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
